Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia

Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective receptor agonist, as a potentia...
Home/KnloSights/Clinical Trial Updates/Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia